GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » I-MAB (NAS:IMAB) » Definitions » YoY EBITDA Growth

I-MAB (IMAB) YoY EBITDA Growth : 52.89% (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is I-MAB YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. I-MAB's YoY EBITDA Growth for the quarter that ended in Dec. 2023 was 52.89%.

I-MAB's EBITDA per Share for the six months ended in Dec. 2023 was $-1.17.

I-MAB YoY EBITDA Growth Historical Data

The historical data trend for I-MAB's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

I-MAB YoY EBITDA Growth Chart

I-MAB Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
YoY EBITDA Growth
Get a 7-Day Free Trial -182.95 132.12 -518.94 10.70 44.04

I-MAB Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -207.00 13.76 4.33 29.63 52.89

I-MAB YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

I-MAB's YoY EBITDA Growth for the fiscal year that ended in Dec. 2023 is calculated as:

YoY EBITDA Growth (A: Dec. 2023 )
=(EBITDA per Share (A: Dec. 2023 )-EBITDA per Share (A: Dec. 2022 ))/ | EBITDA per Share (A: Dec. 2022 ) |
=(-2.376--4.246)/ | -4.246 |
=44.04 %

I-MAB's YoY EBITDA Growth for the quarter that ended in Dec. 2023 is calculated as:

YoY EBITDA Growth (Q: Dec. 2023 )
=(EBITDA per Share (Q: Dec. 2023 )-EBITDA per Share (Q: Dec. 2022 )) / | EBITDA per Share (Q: Dec. 2022 )) |
=(-1.165--2.473)/ | -2.473 |
=52.89 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

I-MAB YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of I-MAB's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

I-MAB (IMAB) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » I-MAB (NAS:IMAB) » Definitions » YoY EBITDA Growth
Comparable Companies
PLX GLSI CDXS CYT SEER PROK MLEC AADI ABSI GOSS OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
0VY:Germany
Address
555 West Haiyang Road, 55th Floor, New Bund Center, Pudong District, Shanghai, CHN, 200124
Website
https://www.i-mabbiopharma.com
I-Mab Biopharma is a clinical-stage biotech company in China that listed on Nasdaq in January 2020. Its first commercial drug will likely be eftansomatropin, a long-acting growth hormone that has a large market in China among pediatric patients with short stature, which we estimate will launch in 2024 or 2025. Other core assets include lemzoparlimab, a potential best-in-class CD47 inhibitor in phase 2 trials; uliledlimab, a potential best-in-class CD73 inhibitor in phase 2 trials; and felzartamab for the Chinese market, a CD38 inhibitor for multiple myeloma, which could have a phase 3 data readout in 2023.